June 17, 2020 / 8:22 PM / 15 days ago

BRIEF-Catalyst Bio - Plans To Initiate Phase 1/2 Trial Of Marzaa In Factor Vii Deficiency, Glanzmann Thrombasthenia, And Hemlibra Patients In Q4

June 17 (Reuters) - Catalyst Biosciences Inc:

* CATALYST BIO - PLANS TO INITIATE PHASE 1/2 TRIAL OF MARZAA IN FACTOR VII DEFICIENCY, GLANZMANN THROMBASTHENIA, AND HEMLIBRA PATIENTS IN Q4 Source text for Eikon: bit.ly/30Swx1W Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below